Hologic
Q2 2022 Earnings Call
Apr 27, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good afternoon, and welcome to the Hologic 2Q '22 earnings conference call. My name is Lauren, and I am your operator for today's call. Today's conference is being recorded. [Operator Instructions] I would now like to introduce Ryan Simon, vice president, investor relations, to begin the call.
Ryan Simon -- Vice President, Investor Relations
Thank you, Lauren. Good afternoon, and thank you for joining Hologic's second quarter fiscal 2022 earnings call. With me today are Steve MacMillan, the company's chairman, president, and chief executive officer; and Karleen Oberton, our chief financial officer. Our second quarter press release is available now on the investors' section of our website, along with an updated corporate presentation.
We will also post our prepared remarks to our website shortly after we deliver them. And a replay of this call will be available through May 27th. Before we begin, we would like to inform you that certain statements we make today will be forward-looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied.
Such factors include those referenced in the safe harbor statement included in our earnings release and SEC filings. Also during this call, we will discuss certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release. Two of these non-GAAP measures are: one, organic revenue, which we define as constant currency revenue, excluding the divested blood screening business and revenue from acquired businesses owned by Hologic for less than one year; and two, organic revenue, excluding COVID-19, which excludes COVID-19 assay revenue, revenue related to COVID-19, and discontinued product sales in Diagnostics.
Finally, any percentage changes we discuss will be on a year-over-year basis, and revenue growth rates will be in constant currency unless otherwise noted. Now I'd like to turn the call over to Steve MacMillan, Hologic's CEO.
Steve MacMillan -- Chairman, President, and Chief Executive Officer
Thank you, Ryan, and good afternoon, everyone. We are pleased to discuss our financial results for the second quarter of fiscal 2022. We posted solid results overall and continued our excellent performance. Total revenue was $1.44 billion, and non-GAAP earnings per share were $2.07, exceeding the midpoint of our guidance by over 12% on the top line and over 33% on the bottom.